JUPITER, Florida, August 21, 2026, 11:25 EDT — Jupiter Neurosciences, Inc. NASDAQ:JUNS surged 59.4% to $8.24 by 11:16:20 EDT. More than 45.3 million shares had changed hands. That volume was about 59 times the company’s entire reported share count.
- JUNS traded 58.8 times its 770,081 reported shares by late morning.
- The stock remained 26.4% below its $11.20 intraday high.
- Its $6.35 million market value stayed far below Nasdaq’s $35 million threshold.
The turnover points to a technical, low-float move rather than a disclosed business change. No newer company filing appeared after the August 14 quarterly report in the SEC filing history checked Friday. That makes the trading mechanics the clearest investor signal.
The rally added about $2.36 million of market value from Thursday’s close. Yet the shares gave back much of their early spike. The price stood $2.96 below the session high.
| Market snapshot | August 21, 11:16:20 EDT | Comparison |
|---|---|---|
| Price | $8.24 | +59.4% from $5.17 close |
| Intraday range | $7.66–$11.20 | 26.4% below high |
| Volume | 45.31 million | 58.8× reported shares |
| Market value | $6.35 million | +$2.36 million vs prior close |
The share count is unusually small because Jupiter completed a one-for-75 reverse split on August 6. Split-adjusted trading began the next day. The transaction cut about 57.8 million shares to roughly 770,000.
That structure can amplify price moves. A single share may also trade many times during one session, so volume does not prove that every share changed owners 59 times. It does show exceptional churn.
| Turnover measure | Value | Investor read-through |
|---|---|---|
| Reported shares outstanding | 770,081 | Small post-split base |
| Friday volume by 11:16 EDT | 45,310,948 | Exceptional activity |
| Volume / reported shares | 58.8× | High intraday recycling likely |
| August 14 volume | About 104,800 | Friday pace exceeded it by 400× |
The reverse split addressed Nasdaq’s $1 minimum-bid rule. Jupiter said it had until August 25 to restore compliance, generally through ten consecutive business-day closes above $1. The company also warned that a reverse split alone did not ensure continued listing.
A second test remains harder. Nasdaq separately requires at least $35 million in market value of listed securities under the standard cited in Jupiter’s filing. Friday’s $6.35 million value covered only 18.1% of that amount.
| Nasdaq measure | Observed level | Threshold math |
|---|---|---|
| Market value of listed securities | $6.35 million | $28.65 million short |
| Required threshold | $35.00 million | 5.52× current value |
| Implied price at current share count | $45.45 | 451.6% above $8.24 |
| Minimum-bid price | $1.00 | Already exceeded Friday |
Fundamentals provide a sharp contrast. Jupiter reported $42,897 of net revenue for the first half. Its net loss reached $4.34 million, while operating activities used $3.73 million of cash.
Cash totaled $1.52 million on June 30. That equaled 40.8% of first-half operating cash use. The company said conditions raised substantial doubt about its ability to continue as a going concern.
| First-half financial measure | Reported amount | Market comparison |
|---|---|---|
| Net revenue | $42,897 | Market value was 148× revenue |
| Net loss | $4.34 million | Friday value gain equaled 54.5% |
| Operating cash used | $3.73 million | Cash covered 40.8% |
| Cash at June 30 | $1.52 million | Market value was 4.17× cash |
Jupiter is developing Nugevia and a Parkinson’s program built around JOTROL. Those programs offer clinical upside, but Friday’s filing record contained no new trial result. The absence of a fresh disclosure increases the weight investors should place on liquidity and listing risk.
Published analyst data are thin and inconsistent. Some snapshots also predate the reverse split. Their dollar targets therefore should not be treated as comparable with Friday’s post-split price.
| Analyst-data source | Displayed view | Displayed target | Usability |
|---|---|---|---|
| Zacks snapshot | 2.00 average from two firms | $25 | Pre-split snapshot; not directly comparable |
| Investing.com snapshot | Strong Buy from one analyst | $30 | Single estimate; split timing makes comparison uncertain |
| PriceTargets snapshot | Sell from one analyst | None shown | Single rating; conflicts with other sources |
Risks: The price can reverse quickly after low-float surges. Jupiter may issue shares under its financing arrangements, causing dilution. Clinical setbacks, limited cash and unresolved Nasdaq compliance could also pressure the stock.
